 Maxim analyst has upgraded Indaptus Therapeutics Inc NASDAQ: INDP to Buy from Hold with a 16 price target, an upside of over 100. Analyst Jason McCarthy says, Indaptus is leveraging the ability of attenuated, non-pathogenic gram-negative bacteria to stimulate both innate and adaptive immune responses for oncology indications and infectious diseases. 